[(1R,5R)-8-propan-2-yl-8-azabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: [(1R,5R)-8-propan-2-yl-8-azabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate
• 化学式: C₁₉H₂₇NO₃
• 分子量: 317.4
• InChiKey: VORSMCHHJRVORT-NUJGCVRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] A NASAL COMPOSITION CONTAINING SEA WATER AS STABILITY-IMPROVING EXCIPIENT<br/>[FR] COMPOSITION NASALE CONTENANT DE L'EAU DE MER EN TANT QU'EXCIPIENT D'AMÉLIORATION DE STABILITÉ
  申请人：JADRAN GALENSKI LAB D D

  公开号：WO2016102984A1

  公开（公告）日：2016-06-30

  The invention discloses a nasal composition of improved stability, their use, and process for production. The nasal composition consists of: xylometazoline hydrochloride (1), 0.01-0.1% w/w; ipratropium bromide (2), 0.01-0.1% w/w; and pharmaceutical excipients required to form final dosage forms selected from the group consisting of: nasal drops, liquid nasal sprays, or nasal washes. Said nasal composition comprises the content of purified sea water as functional, stability-improving excipient, in amounts of 5-25% w/w. A nasal composition has osmolality within the range 270-820 mOsm/kg, the pH value within the range 3-7, preferably within the range 3-4.2 or 5.8-7.0, and most preferably within the range 3.2-4.2 where shows improved stability.